EOLS — Evolus Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $5.31
- 30-Day Move
- -26.5%
- Market Cap
- $262M
- Shares Outstanding
- 65,060,000
- P/B Ratio
- 126.6
- ROE
- -913.1%
Analyst consensus: Buy · 13 analysts
Evolus Inc
A read-only Alphactor snapshot forEvolus Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$5.31
30-Day Move
-26.5%
Market Cap
$262M
Shares Outstanding
65,060,000
P/B Ratio
126.6
ROE
-913.1%
$5.31
-26.5%last 90 delayed daily bars
90D High
$7.33
90D Low
$3.86
Avg Volume
1,148,954
Gross margin is running at 66.3%, which gives a quick read on operating quality before you open the full model.
Net margin is -17.4%, useful for comparing EOLS against peers in Pharmaceuticals.
EOLS is down 26.5% over the last 30 trading days shown on this page.
Latest operating income is $-291,000, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$21.28
Rule of 40
-5.5%
Dark Pool Short %
47.1%
Latest Close
$5.31
30-Day Move
-26.5%
Market Cap
$262M
Shares Outstanding
65,060,000
P/B Ratio
126.6
ROE
-913.1%
ROA
-22.9%
Gross Margin
66.3%
Operating Margin
-11.0%
Net Margin
-17.4%
Debt / Equity
22
Current Ratio
1.9
Latest Revenue
$90M
Revenue
$90M
Gross Profit
$59M
Operating Income
$-291,000
Net Income
$130,000
Gross Margin
6633.0%
Net Margin
-1738.0%
Current Ratio
1.90
Debt / Equity
22.00
Fair Value
$21.28
Upside / Downside
+300.8%
Signal
Undervalued
Implied Growth
--
EV/Rev
$21.28
Growth Assumption
26.0%
Discount Rate
11.3%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
-2.34
Distress
Piotroski
2
Weak (0-3)
Cash Conversion
0.82x
Rule of 40
-5.5%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $149M | $-60M | $-74M | $-88M |
| 2023-12-31 | $202M | $-45M | $-62M | $-36M |
| 2024-12-31 | $266M | $-27M | $-50M | $-23M |
| 2025-12-31 | $297M | $-38M | $-52M | $-51M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$393,486
Sell Value
$2M
Buys
2
Sells
12
Buy Value
$393,486
Sell Value
$2M
Buy/Sell Ratio
0.17x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-20 | MOATAZEDI DAVID | Sell | 13,669 | $4.75 |
| 2026-03-20 | Avelar Rui | Sell | 3,119 | $4.75 |
| 2026-03-17 | MOATAZEDI DAVID | Sell | 116,720 | $4.89 |
| 2026-03-17 | Avelar Rui | Sell | 29,996 | $4.89 |
| 2026-03-16 | MOATAZEDI DAVID | M | 67,489 | $0.00 |
| 2026-03-16 | MOATAZEDI DAVID | M | 67,489 | $0.00 |
| 2026-03-16 | Avelar Rui | M | 8,804 | $0.00 |
| 2026-03-16 | Avelar Rui | M | 8,804 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,665,893 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,305,616 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 713,567 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 503,394 | 0.01% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 433,241 | 0.01% | 2026-02-28 |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 310,653 | 0.00% | 2025-11-30 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 287,952 | 0.00% | 2025-11-30 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 244,024 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2026-02-17
--
--
BlackRock
Filed 2024-05-10
$46M
--
Vanguard Group
Filed 2025-05-09
$39M
+2.0%
Geode Capital Management
Filed 2025-08-08
$11M
-2.4%
D.E. Shaw
Filed 2026-02-17
$10M
+13.8%
Citadel Advisors
Filed 2026-02-17
$9M
--
4.23
Consensus
Buy—
—
—
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.